Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
- 8 May 2019
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 176 (3) , 607-615
Abstract
To evaluate the pCR rate and toxicity of the addition of weekly carboplatin (Cp) to paclitaxel (wP) and dose-dense (dd) epirubicin/cyclophosphamide (EC) in an open-label phase II study in TNBC patients.Keywords
Funding Information
- Amgen Nederland
- Teva Pharmaceutical Industries
This publication has 23 references indexed in Scilit:
- The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancerJournal of Geriatric Oncology, 2013
- A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter studyBreast Cancer Research and Treatment, 2012
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled TrialsJNCI: Journal of the National Cancer Institute, 2010
- Metastatic Behavior of Breast Cancer SubtypesJournal of Clinical Oncology, 2010
- Susceptibility Pathways in Fanconi's Anemia and Breast CancerNew England Journal of Medicine, 2010
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2010
- Triple-negative breast cancerCurrent Opinion in Oncology, 2008
- Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapyHistopathology, 2006
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001